Acurx Pharmaceuticals LLC (ACXP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Acurx Pharmaceuticals LLC (ACXP) has a cash flow conversion efficiency ratio of -0.201x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.41 Billion) by net assets ($7.01 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ACXP defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Acurx Pharmaceuticals LLC - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Acurx Pharmaceuticals LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Acurx Pharmaceuticals LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acurx Pharmaceuticals LLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Porvair plc
LSE:PRV
|
0.095x |
|
Oakajee Corporation Ltd
AU:OKJ
|
-0.189x |
|
Pomvom
TA:PMVM
|
0.429x |
|
Infinity Lithium Corporation Ltd
AU:INF
|
-0.258x |
|
Pelangi Indah Canindo Tbk
JK:PICO
|
0.047x |
|
CN Asia Corporation Bhd
KLSE:7986
|
0.017x |
|
Parx Plastics NV
PA:MLPRX
|
N/A |
|
Amatheon Agri Holding NV
PA:MLAAH
|
-0.204x |
Annual Cash Flow Conversion Efficiency for Acurx Pharmaceuticals LLC (2019–2025)
The table below shows the annual cash flow conversion efficiency of Acurx Pharmaceuticals LLC from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Acurx Pharmaceuticals LLC stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.27 Million | $-6.79 Billion | -1288.348x | -7532.26% |
| 2024-12-31 | $615.12K | $-10.38 Million | -16.880x | -703.75% |
| 2023-12-31 | $4.67 Million | $-9.80 Million | -2.100x | -103.69% |
| 2022-12-31 | $7.32 Million | $-7.54 Million | -1.031x | -155.22% |
| 2021-12-31 | $12.41 Million | $-5.01 Million | -0.404x | +67.44% |
| 2020-12-31 | $2.70 Million | $-3.35 Million | -1.241x | +74.48% |
| 2019-12-31 | $819.85K | $-3.99 Million | -4.861x | -- |
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more